CY1123350T1 - Θεραπευτικα σχηματα καi μεθοδοι αντιμετωπισης σκληρυνσης κατα πλακας μεσω χρησης οφατουμουμαμπης - Google Patents
Θεραπευτικα σχηματα καi μεθοδοι αντιμετωπισης σκληρυνσης κατα πλακας μεσω χρησης οφατουμουμαμπηςInfo
- Publication number
- CY1123350T1 CY1123350T1 CY20201100861T CY201100861T CY1123350T1 CY 1123350 T1 CY1123350 T1 CY 1123350T1 CY 20201100861 T CY20201100861 T CY 20201100861T CY 201100861 T CY201100861 T CY 201100861T CY 1123350 T1 CY1123350 T1 CY 1123350T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- methods
- shelder
- ofatumumambi
- plaque
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Meat, Egg Or Seafood Products (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pressure Welding/Diffusion-Bonding (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662374986P | 2016-08-15 | 2016-08-15 | |
| PCT/IB2017/054909 WO2018033841A1 (en) | 2016-08-15 | 2017-08-11 | Regimens and methods of treating multiple sclerosis using ofatumumab |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123350T1 true CY1123350T1 (el) | 2021-12-31 |
Family
ID=59901554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100861T CY1123350T1 (el) | 2016-08-15 | 2020-09-11 | Θεραπευτικα σχηματα καi μεθοδοι αντιμετωπισης σκληρυνσης κατα πλακας μεσω χρησης οφατουμουμαμπης |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US11161909B2 (https=) |
| EP (5) | EP3497132B1 (https=) |
| JP (2) | JP6851391B2 (https=) |
| KR (2) | KR20200136503A (https=) |
| CN (5) | CN120000782A (https=) |
| AU (2) | AU2017311664C1 (https=) |
| CA (2) | CA3030530C (https=) |
| CY (1) | CY1123350T1 (https=) |
| DE (1) | DE202017007542U1 (https=) |
| DK (2) | DK3733712T3 (https=) |
| ES (2) | ES2954259T3 (https=) |
| FI (1) | FI3733712T3 (https=) |
| HR (2) | HRP20230894T1 (https=) |
| HU (2) | HUE063625T2 (https=) |
| IL (4) | IL302488B2 (https=) |
| LT (2) | LT3733712T (https=) |
| MX (1) | MX388593B (https=) |
| PL (2) | PL3497132T3 (https=) |
| PT (2) | PT3733712T (https=) |
| RS (2) | RS60807B1 (https=) |
| RU (1) | RU2749951C2 (https=) |
| SI (2) | SI3497132T1 (https=) |
| TW (1) | TWI752995B (https=) |
| WO (1) | WO2018033841A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3733712T (lt) | 2016-08-15 | 2023-09-11 | Novartis Ag | Išsėtinės sklerozės gydymo schemos ir būdai, panaudojant ofatumumabą |
| MX2022003010A (es) * | 2019-09-11 | 2022-06-02 | Novartis Ag | Tratamiento de la emr mediante cambio de terapia. |
| US20220389109A1 (en) * | 2019-09-11 | 2022-12-08 | Novartis Ag | Management of conditions other than multiple sclerosis in ofatumumab-treated patients |
| EP4707302A2 (en) * | 2020-04-09 | 2026-03-11 | Novartis AG | Ofatumumab for treating ms while maintaining serum igg |
| WO2022219057A1 (en) * | 2021-04-14 | 2022-10-20 | Novartis Ag | Ofatumumab for treating multiple sclerosis in asian patients |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US4816401A (en) | 1985-09-09 | 1989-03-28 | University Of Rochester | Serum free cell culture medium |
| DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| US20020064823A1 (en) | 2000-03-30 | 2002-05-30 | Welcher Andrew A. | CD20/IgE-receptor like molecules and uses thereof |
| EA013564B1 (ru) | 2000-08-03 | 2010-06-30 | Терапеутик Хьюман Поликлоналз Инк. | Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция |
| BRPI0315295C1 (pt) | 2002-10-17 | 2021-05-25 | Genmab As | anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| DOP2006000029A (es) | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
| CA2631184A1 (en) | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| UA107557C2 (xx) | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| AR073295A1 (es) | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
| WO2012018704A1 (en) | 2010-08-02 | 2012-02-09 | Sanofi-Aventis U.S. Llc | Use of teriflunomide for treating multiple sclerosis |
| EP2663331A4 (en) * | 2011-01-10 | 2015-07-15 | Glaxosmithkline Intellectual Property Man Ltd | NEW USES |
| WO2013120012A2 (en) | 2012-02-08 | 2013-08-15 | Igm Biosciences Inc. | Cdim binding proteins and uses thereof |
| EP2692343A1 (en) | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Combination therapy for treatment of multiple sclerosis |
| SG11201500499TA (en) | 2012-08-10 | 2015-03-30 | Boehringer Ingelheim Int | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors |
| WO2015162504A1 (en) | 2014-04-23 | 2015-10-29 | Novartis Ag | Novel dosing and uses of ofatumumab |
| WO2015168103A1 (en) | 2014-04-29 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| JP2018506275A (ja) * | 2015-01-28 | 2018-03-08 | ジェネンテック， インコーポレイテッド | 多発性硬化症の遺伝子発現マーカー及び治療 |
| CN106699886A (zh) | 2015-07-13 | 2017-05-24 | 西藏海思科药业集团股份有限公司 | 抗体依赖性细胞介导的细胞毒性(adcc)增强的奥法木抗体 |
| LT3733712T (lt) | 2016-08-15 | 2023-09-11 | Novartis Ag | Išsėtinės sklerozės gydymo schemos ir būdai, panaudojant ofatumumabą |
| US20220389109A1 (en) | 2019-09-11 | 2022-12-08 | Novartis Ag | Management of conditions other than multiple sclerosis in ofatumumab-treated patients |
| MX2022003010A (es) | 2019-09-11 | 2022-06-02 | Novartis Ag | Tratamiento de la emr mediante cambio de terapia. |
| EP4707302A2 (en) | 2020-04-09 | 2026-03-11 | Novartis AG | Ofatumumab for treating ms while maintaining serum igg |
| WO2022219057A1 (en) | 2021-04-14 | 2022-10-20 | Novartis Ag | Ofatumumab for treating multiple sclerosis in asian patients |
| US20240343821A1 (en) | 2021-08-16 | 2024-10-17 | Novartis Ag | Ofatumumab for treating pediatric ms |
-
2017
- 2017-08-11 LT LTEP20180938.1T patent/LT3733712T/lt unknown
- 2017-08-11 IL IL302488A patent/IL302488B2/en unknown
- 2017-08-11 RS RS20201066A patent/RS60807B1/sr unknown
- 2017-08-11 HU HUE20180938A patent/HUE063625T2/hu unknown
- 2017-08-11 EP EP17768863.7A patent/EP3497132B1/en active Active
- 2017-08-11 EP EP25225892.6A patent/EP4711008A2/en active Pending
- 2017-08-11 HU HUE17768863A patent/HUE051948T2/hu unknown
- 2017-08-11 DE DE202017007542.3U patent/DE202017007542U1/de active Active
- 2017-08-11 DK DK20180938.1T patent/DK3733712T3/da active
- 2017-08-11 AU AU2017311664A patent/AU2017311664C1/en active Active
- 2017-08-11 PT PT201809381T patent/PT3733712T/pt unknown
- 2017-08-11 PL PL17768863T patent/PL3497132T3/pl unknown
- 2017-08-11 CN CN202510270924.1A patent/CN120000782A/zh active Pending
- 2017-08-11 HR HRP20230894TT patent/HRP20230894T1/hr unknown
- 2017-08-11 JP JP2018550539A patent/JP6851391B2/ja active Active
- 2017-08-11 IL IL276890A patent/IL276890B2/en unknown
- 2017-08-11 RU RU2019107146A patent/RU2749951C2/ru active
- 2017-08-11 FI FIEP20180938.1T patent/FI3733712T3/fi active
- 2017-08-11 MX MX2019001860A patent/MX388593B/es unknown
- 2017-08-11 US US16/324,619 patent/US11161909B2/en active Active
- 2017-08-11 KR KR1020207034140A patent/KR20200136503A/ko not_active Ceased
- 2017-08-11 KR KR1020197007454A patent/KR20190038914A/ko not_active Ceased
- 2017-08-11 CN CN202510270941.5A patent/CN120053638A/zh active Pending
- 2017-08-11 HR HRP20201388TT patent/HRP20201388T1/hr unknown
- 2017-08-11 PL PL20180938.1T patent/PL3733712T3/pl unknown
- 2017-08-11 WO PCT/IB2017/054909 patent/WO2018033841A1/en not_active Ceased
- 2017-08-11 CA CA3030530A patent/CA3030530C/en active Active
- 2017-08-11 LT LTEP17768863.7T patent/LT3497132T/lt unknown
- 2017-08-11 CN CN201780049932.7A patent/CN109641965A/zh active Pending
- 2017-08-11 EP EP20180938.1A patent/EP3733712B1/en active Active
- 2017-08-11 RS RS20230635A patent/RS64541B1/sr unknown
- 2017-08-11 IL IL313932A patent/IL313932A/en unknown
- 2017-08-11 CN CN202510270903.XA patent/CN120037367A/zh active Pending
- 2017-08-11 EP EP23172507.8A patent/EP4252847A3/en active Pending
- 2017-08-11 ES ES20180938T patent/ES2954259T3/es active Active
- 2017-08-11 CA CA3101514A patent/CA3101514A1/en active Pending
- 2017-08-11 CN CN202510270961.2A patent/CN120053639A/zh active Pending
- 2017-08-11 PT PT177688637T patent/PT3497132T/pt unknown
- 2017-08-11 ES ES17768863T patent/ES2821924T3/es active Active
- 2017-08-11 DK DK17768863.7T patent/DK3497132T3/da active
- 2017-08-11 EP EP24166956.3A patent/EP4371611A3/en active Pending
- 2017-08-11 SI SI201730400T patent/SI3497132T1/sl unknown
- 2017-08-11 SI SI201731396T patent/SI3733712T1/sl unknown
- 2017-08-15 TW TW106127565A patent/TWI752995B/zh active
-
2019
- 2019-02-12 IL IL264804A patent/IL264804B/en active IP Right Grant
-
2020
- 2020-02-07 JP JP2020019337A patent/JP7198786B2/ja active Active
- 2020-02-17 AU AU2020201112A patent/AU2020201112C1/en active Active
- 2020-09-11 CY CY20201100861T patent/CY1123350T1/el unknown
-
2021
- 2021-10-06 US US17/495,559 patent/US20220081488A1/en not_active Abandoned
-
2023
- 2023-06-08 US US18/331,701 patent/US12570754B2/en active Active
-
2024
- 2024-03-06 US US18/597,624 patent/US12338290B2/en active Active
-
2025
- 2025-05-28 US US19/221,422 patent/US20250289902A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123350T1 (el) | Θεραπευτικα σχηματα καi μεθοδοι αντιμετωπισης σκληρυνσης κατα πλακας μεσω χρησης οφατουμουμαμπης | |
| MX2020005651A (es) | Receptor de antigeno quimerico dirigido a bcma y usos del mismo. | |
| CY1123688T1 (el) | Μεθοδοι για τη θεραπευτικη αντιμετωπιση ογκων χρησιμοποιωντας αμφιειδικο αντισωμα cd3xcd20 | |
| CY1125621T1 (el) | Μεθοδοι για τη θεραπευτικη αντιμετωπιση των διαταραχων ανωμαλης, ακουσιας κινησης | |
| CY1123256T1 (el) | Συζευγματα αντισωματος enanti-cmet δραστικης ουσιας και μεθοδοι για τη χρηση αυτων | |
| CY1125213T1 (el) | Μεθοδοι θεραπειας καρκινου του μαστου ar+ | |
| CY1125247T1 (el) | Μεθοδοι θεραπειας καταθλιψης χρησιμοποιωντας ανταγωνιστες υποδοχεα ορεξινης-2 | |
| CL2018002727A1 (es) | Medicina obtenida mediante la combinación de agonista fxr y arb | |
| CO2020004831A2 (es) | Dosis y administración de anticuerpos antic-c5 para el tratamiento de pacientes con glomerulonefritis membranoproliferativa | |
| MX2020000190A (es) | Métodos para tratar la insuficiencia cardíaca con activadores de sarcómero cardíaco. | |
| EA201692436A1 (ru) | Медицинское применение | |
| CL2017001756A1 (es) | Régimen de dosificación para antagonistas de madcam. | |
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| EA201790164A1 (ru) | Комбинированная терапия рака | |
| EA201892190A1 (ru) | Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы | |
| MX2021004120A (es) | Regimen de dosificacion para antagonistas de tfpi. | |
| EA201992278A1 (ru) | Способы и композиции для снижения иммуногенности | |
| MX2018002554A (es) | Combinaciones de inhibidores de btk para tratar mieloma multiple. | |
| MX2017001461A (es) | Terapia de combinacion. | |
| CY1120176T1 (el) | Μεθοδος για τη μειωση των συμπτωματων που μοιαζουν με αυτα της γριπης που συνδεονται με ενδομυϊκη χορηγηση ιντερφερονης με τη χρηση ενος σχηματος κλιμακουμενης δοσολογιας ταχειας τιτλοδοτησης | |
| CR20220127A (es) | Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1 | |
| EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
| MX2020004074A (es) | Producto de combinacion para el tratamiento de cancer. | |
| MX2022005245A (es) | Regimen de dosificacion de anticuerpos anti-cd27 para el tratamiento de cancer. | |
| MX2021013248A (es) | Regimenes de dosificacion para anticuerpos anti-vrs y composiciones que los incluyen. |